scholarly journals Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression

2012 ◽  
Vol 97 (7) ◽  
pp. 2362-2369 ◽  
Author(s):  
S. Tuvia ◽  
J. Atsmon ◽  
S. L. Teichman ◽  
S. Katz ◽  
P. Salama ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Effective Growth ◽  
Growth Hormone Suppression

Growth hormone signaling and action in obese versus lean human subjects: evidence of increased hepatic GH sensitivity in obesity

2017 ◽  
Author(s):  
Morten Hogild Pedersen ◽  
Ann Mosegaard Bak ◽  
Steen Bonlokke Pedersen ◽  
Niels Jessen ◽  
Niels Moller ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Hormone Signaling

METABOLIC EFFECTS OF “PITUITARY GROWTH HORMONE PREPARATIONS” IN HUMAN SUBJECTS SUMMARY OF QUANTITATIVE STUDIES EXTENDING OVER A FIVE-YEAR PERIOD

1954 ◽  
Vol 14 (1) ◽  
pp. 110-117 ◽  
Author(s):  
LAURANCE W. KINSELL ◽  
SHELDON MARGEN ◽  
JOHN W. PARTRIDGE ◽  
GEORGE D. MICHAELS ◽  
HARRY E. BALCH ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Metabolic Effects ◽  
Pituitary Growth Hormone ◽  
Quantitative Studies

scholarly journals Growth hormone signaling and action in obese versus lean human subjects

2019 ◽  
Vol 316 (2) ◽  
pp. E333-E344 ◽  
Author(s):  
Morten Lyng Høgild ◽  
Ann Mosegaard Bak ◽  
Steen Bønløkke Pedersen ◽  
Jørgen Rungby ◽  
Jan Frystyk ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Growth Hormone ◽  
Human Subjects ◽  
Glucose Production ◽  
Relative Increase ◽  
Antagonistic Effect ◽  
Endogenous Glucose Production ◽  
Metabolic Adaptation ◽  
Igf I

Growth hormone (GH) levels are blunted in obesity, but it is not known whether this relates to altered GH sensitivity and whether this influences the metabolic adaptation to fasting. Therefore, we investigated the effect of obesity on GH signal transduction and fasting-induced changes in GH action. Nine obese (BMI 35.7 kg/m2) and nine lean (BMI 21.5 kg/m2) men were studied in a randomized crossover design with 1) an intravenous GH bolus, 2) an intravenous saline bolus, and 3) 72 h of fasting. Insulin sensitivity (hyperinsulinemic, euglycemic clamp) and substrate metabolism (glucose tracer and indirect calorimetry) were measured in studies 1 and 2. In vivo GH signaling was assessed in muscle and fat biopsies. GH pharmacokinetics did not differ between obese and lean subjects, but endogenous GH levels were reduced in obesity. GH signaling (STAT5b phosphorylation and CISH mRNA transcription), and GH action (induction of lipolysis and peripheral insulin resistance) were similar in the two groups, but a GH-induced insulin antagonistic effect on endogenous glucose production only occurred in the obese. Fasting-induced IGF-I reduction was completely abrogated in obese subjects despite a comparable relative increase in GH levels (ΔIGF-I: lean, −66 ± 10 vs. obese, 27 ± 16 µg/l; P < 0.01; ΔGH: lean, 647 ± 280 vs. obese, 544 ± 220%; P = 0.76]. We conclude that 1) GH signaling is normal in obesity, 2) in the obese state, the preservation of IGF-I with fasting and the augmented GH-induced central insulin resistance indicate increased hepatic GH sensitivity, 3) blunted GH levels in obesity may protect against insulin resistance without compromising IGF-I status.

Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients

1993 ◽  
Vol 129 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Yi-Fan Shi ◽  
Xian-Feng Zhu ◽  
Alan G Harris ◽  
Jin-Xi Zhang ◽  
Jie-Ying Deng
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Term Therapy ◽  
Serum Growth Hormone ◽  
Factor I ◽  
Gallbladder Contractility ◽  
Octreotide Therapy ◽  
Long Term Therapy ◽  
Growth Hormone Suppression

We sought to examine how the discontinuation of octreotide in long-term octreotide-treated acromegalic patients affects the well-documented side-effect of cholelithiasis. In 14 acromegalic patients, serum growth hormone levels, insulin-like growth factor I levels and percentage of relative gallbladder contractility were measured prior to and after the discontinuation of octreotide. Compared to pretreatment values, the basal growth hormone and 5-h growth hormone profiles were 36% and 24%, and 60% and 56% at the end of 1 and 2 weeks, respectively. Octreotide was found to be eliminated completely from the serum within 3 days after its withdrawal. In all of six patients who did not develop gallstones, the percentage relative gallbladder contractility normalized within 1 week. In eight patients who developed gallstones, four of them had restoration of normal contractility within 2 weeks. Our results show that upon withdrawal of octreotide, gallbladder contractility returns to normal while growth hormone suppression persists for a longer period of time. Therefore, discontinuation of octreotide therapy may allow for the clearance of stagnated bile and hence decrease the incidence of cholelithiasis in acromegalic patients receiving long-term therapy.

scholarly journals Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects

2021 ◽  
pp. 106030
Author(s):  
Hans Helleberg ◽  
Mads Bjelke ◽  
Birgitte Bentz Damholt ◽  
Palle Jacob Pedersen ◽  
Michael Højby Rasmussen
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Long Acting

An experience of effective growth hormone therapy for idiopathic dilated cardiomyopathy

1998 ◽  
Vol 4 (3) ◽  
pp. 111
Author(s):  
Kazuo Komamura ◽  
Takanori Tsukada ◽  
Masakazu Yamagishi ◽  
Chikao Yutani ◽  
Kunio Miyatake
Keyword(s):  
Growth Hormone ◽  
Dilated Cardiomyopathy ◽  
Hormone Therapy ◽  
Growth Hormone Therapy ◽  
Idiopathic Dilated Cardiomyopathy ◽  
Effective Growth

SERUM THYROTROPHIN, PROLACTIN AND GROWTH HORMONE, RESPONSE TO TRH DURING OESTROGEN TREATMENT

1977 ◽  
Vol 84 (1) ◽  
pp. 23-35 ◽  
Author(s):  
E. Rutlin ◽  
E. Haug ◽  
P. A. Torjesen
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Serum Levels ◽  
Normal Male ◽  
Oestrogen Treatment ◽  
Thyrotrophin Releasing Hormone ◽  
Basal Serum ◽  
Menopausal Women ◽  
Menstruating Women ◽  
Post Menopausal

ABSTRACT The serum levels of thyrotrophin (TSH), prolactin (PRL) and growth hormone (GH) and the response of these hormones to 500 μg thyrotrophin-releasing hormone (TRH) iv were studied in menstruating women. in post-menopausal women before and after 2 mg oestradiol valerate for 5 consecutive days, and in men on long term oestrogen treatment. Oestrogen treatment had no effect on basal serum TSH levels, which were within the normal range in all groups. The TSH response to TRH was not different in menstruating and post-menopausal women and was not changed in the latter group after oestrogen treatment. In men treated chronically with oestrogens, the TSH response to TRH was similar to that found in normal male subjects. There was no difference in basal levels of serum PRL between males and menstruating females. In the post-menopausal women, however, basal levels of serum PRL was significantly decreased, but rose during oestrogen treatment to serum levels normally found in menstruating women. In the oestrogen treated males basal serum PRL levels were significantly higher than in untreated men. The PRL response to TRH was significantly greater in females than in males, but in the oestrogen treated males the PRL response to TRH was greatly increased and almost of the same magnitude as the response in females. There was no difference in PRL response between menstruating and post-menopausal women, and oestrogen treatment of the latter group had no significant effect on the PRL response. Basal levels of serum GH did not differ between the groups. In the group of 9 post-menopausal women one subject showed a small GH response to TRH prior to oestrogen treatment, while 7 subjects showed GH responses to TRH after oestrogen treatment. In the group of 5 chronically oestrogen treated men, 2 subjects had increased serum levels of GH after TRH. Thus our data show that oestrogen administration may induce PRL release in human subjects, while oestrogens seem to play a far less important role in the regulation of GH and TSH secretion.

Effect of exogenous β-endorphin on anterior pituitary hormone secretion in man

1982 ◽  
Vol 99 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Tsutomu Oyama ◽  
Ryuji Yamaya ◽  
Toshiro Jin ◽  
Tsuyoshi Kudo
Keyword(s):  
Growth Hormone ◽  
Anterior Pituitary ◽  
Human Subjects ◽  
Hormone Secretion ◽  
Plasma Concentrations ◽  
Adrenocortical Function ◽  
Control Group ◽  
Pituitary Hormone ◽  
Plasma Acth ◽  
Anterior Pituitary Hormone

Abstract. The effect of large amounts of synthesized human β-endorphin (β-Ep) administered intrathecally on pituitary-adrenocortical function was investigated by determining the plasma levels of ACTH, cortisol, growth hormone and prolactin in 8 patients with pain caused by severe disseminated cancer. They were divided into 2 groups, an Ep group of 8 patients and a control group of 5 of the same 8 patients. There were no significant effects of β-Ep on plasma ACTH, cortisol and growth hormone levels. However, the injection of β-Ep into human subjects resulted in a rise in plasma concentrations of prolactin.

Sign in / Sign up

Export Citation Format

Share Document